Humoral and cellular responses to SARS-CoV-2 vaccination in patients with autoantibody-mediated neuroimmunology

Introduction COVID-19 caused by SARS-CoV-2 is still prevalent worldwide. In Japan, two types of mRNA vaccines, BNT162b2 and mRNA-1273, have been widely administered. Neuromyelitis optica spectrum disorder (NMOSD) and myasthenia gravis (MG) are representative autoantibody-mediated neuroimmunological diseases. Majority of the patients are required to take immunosuppressive medication. In this regard, there is an urgent need to clarify the immune responses elicited by SARS-CoV-2 mRNA vaccination to elucidate its efficacy and the potential immune flare in these patients. Insufficient humoral immune responses and potent SARS-CoV-2 spike (S)-specific CD4+ T-cell responses were shown in patients with NMOSD. Alteration of follicular helper T (Tfh) cell phenotype may attenuate the production of anti-S antibody and indicate potential risk of immune flare of the disease activity. Results Demographic and clinical characteristics of the patients were shown in . One patient in each of NMOSD and MG groups developed COVID-19 within 6...
Source: Journal of Neurology, Neurosurgery and Psychiatry - Category: Neurosurgery Authors: Tags: COVID-19 PostScript Source Type: research